Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BZZ5

UPID:
API5_HUMAN

ALTERNATIVE NAMES:
Antiapoptosis clone 11 protein; Cell migration-inducing gene 8 protein; Fibroblast growth factor 2-interacting factor; Protein XAGL

ALTERNATIVE UPACC:
Q9BZZ5; B4DGR0; B4DRJ2; B4E283; D3DR21; G3V1C3; O15441; Q9Y4J7

BACKGROUND:
The protein Apoptosis Inhibitor 5, with aliases such as Antiapoptosis clone 11 protein and Fibroblast growth factor 2-interacting factor, serves as a pivotal antiapoptotic factor. It has a significant role in protein assembly, negatively impacts ACIN1, and suppresses ACIN1 cleavage and DNA fragmentation mediated by ACIN1. Its ability to efficiently counteract E2F1-induced apoptosis highlights its importance in cellular survival mechanisms.

THERAPEUTIC SIGNIFICANCE:
The exploration of Apoptosis Inhibitor 5's function offers promising avenues for therapeutic intervention, particularly in leveraging its role to amplify the effectiveness of chemotherapeutic agents.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.